26MAR201303272455
2012 ANNUAL REPORT 26MAR201303272455
• Emerging life science Company developing high-potential drugs to address unmet needs, leveraging its current operating business infrastructure to penetrate the renal market, once FDA approved.
• Proprietary iron-delivery drug SFP has the potential to change the standard of care in treating anemia in hemodialysis.